Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of palliative medicine 2022-03, Vol.11 (3), p.1126-1134
Hauptverfasser: Song, Zizheng, Ren, Guanying, Wang, Xiaolei, Du, Haiwei, Sun, Ying, Hu, Ling
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1134
container_issue 3
container_start_page 1126
container_title Annals of palliative medicine
container_volume 11
creator Song, Zizheng
Ren, Guanying
Wang, Xiaolei
Du, Haiwei
Sun, Ying
Hu, Ling
description
doi_str_mv 10.21037/apm-21-3731
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_21037_apm_21_3731</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_21037_apm_21_3731</sourcerecordid><originalsourceid>FETCH-LOGICAL-c236t-490906be3fbc0b36bfb54301d4081d8868bb85be3f3e2fbf7ec6e2eee4d319d43</originalsourceid><addsrcrecordid>eNo9kN1Kw0AQhYMoWLR3PsA8gNH9SdPEO6m1CgVB1NswuzurK8mm7m4svpjPZ1rFqzmcc5gDX5adcXYhOJPzS9x0ueC5nEt-kE2EEEU-q2R9-K8FO86mMb4zxriQVVGLSfZ9MwRULYFunXcaW1DkyboENvQdoMU0-gqcB4R28K-AhnyvMWjn-w5hMxbIJ9i69AaoPwYXyMBydfsI6zmvXqAb0ljpfd6RcZjGMFB0MaHXBKnfYjAR-ug6Cvupq3FIY6SxtulDAvQGWpcoYBrCzv10tD3Njiy2kaZ_9yR7vl0-Le7y9cPqfnG9zrWQZcqLmtWsVCSt0kzJUlk1KyTjpmAVN1VVVkpVs10uSVhl56RLEkRUGMlrU8iT7Pz3rw59jIFsswmuw_DVcNbssTcj9lE1O-zyB3E5eo4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Song, Zizheng ; Ren, Guanying ; Wang, Xiaolei ; Du, Haiwei ; Sun, Ying ; Hu, Ling</creator><creatorcontrib>Song, Zizheng ; Ren, Guanying ; Wang, Xiaolei ; Du, Haiwei ; Sun, Ying ; Hu, Ling</creatorcontrib><identifier>ISSN: 2224-5820</identifier><identifier>EISSN: 2224-5839</identifier><identifier>DOI: 10.21037/apm-21-3731</identifier><language>eng</language><ispartof>Annals of palliative medicine, 2022-03, Vol.11 (3), p.1126-1134</ispartof><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c236t-490906be3fbc0b36bfb54301d4081d8868bb85be3f3e2fbf7ec6e2eee4d319d43</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Song, Zizheng</creatorcontrib><creatorcontrib>Ren, Guanying</creatorcontrib><creatorcontrib>Wang, Xiaolei</creatorcontrib><creatorcontrib>Du, Haiwei</creatorcontrib><creatorcontrib>Sun, Ying</creatorcontrib><creatorcontrib>Hu, Ling</creatorcontrib><title>Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review</title><title>Annals of palliative medicine</title><issn>2224-5820</issn><issn>2224-5839</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNo9kN1Kw0AQhYMoWLR3PsA8gNH9SdPEO6m1CgVB1NswuzurK8mm7m4svpjPZ1rFqzmcc5gDX5adcXYhOJPzS9x0ueC5nEt-kE2EEEU-q2R9-K8FO86mMb4zxriQVVGLSfZ9MwRULYFunXcaW1DkyboENvQdoMU0-gqcB4R28K-AhnyvMWjn-w5hMxbIJ9i69AaoPwYXyMBydfsI6zmvXqAb0ljpfd6RcZjGMFB0MaHXBKnfYjAR-ug6Cvupq3FIY6SxtulDAvQGWpcoYBrCzv10tD3Njiy2kaZ_9yR7vl0-Le7y9cPqfnG9zrWQZcqLmtWsVCSt0kzJUlk1KyTjpmAVN1VVVkpVs10uSVhl56RLEkRUGMlrU8iT7Pz3rw59jIFsswmuw_DVcNbssTcj9lE1O-zyB3E5eo4</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>Song, Zizheng</creator><creator>Ren, Guanying</creator><creator>Wang, Xiaolei</creator><creator>Du, Haiwei</creator><creator>Sun, Ying</creator><creator>Hu, Ling</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20220301</creationdate><title>Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review</title><author>Song, Zizheng ; Ren, Guanying ; Wang, Xiaolei ; Du, Haiwei ; Sun, Ying ; Hu, Ling</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c236t-490906be3fbc0b36bfb54301d4081d8868bb85be3f3e2fbf7ec6e2eee4d319d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Song, Zizheng</creatorcontrib><creatorcontrib>Ren, Guanying</creatorcontrib><creatorcontrib>Wang, Xiaolei</creatorcontrib><creatorcontrib>Du, Haiwei</creatorcontrib><creatorcontrib>Sun, Ying</creatorcontrib><creatorcontrib>Hu, Ling</creatorcontrib><collection>CrossRef</collection><jtitle>Annals of palliative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Song, Zizheng</au><au>Ren, Guanying</au><au>Wang, Xiaolei</au><au>Du, Haiwei</au><au>Sun, Ying</au><au>Hu, Ling</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review</atitle><jtitle>Annals of palliative medicine</jtitle><date>2022-03-01</date><risdate>2022</risdate><volume>11</volume><issue>3</issue><spage>1126</spage><epage>1134</epage><pages>1126-1134</pages><issn>2224-5820</issn><eissn>2224-5839</eissn><doi>10.21037/apm-21-3731</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2224-5820
ispartof Annals of palliative medicine, 2022-03, Vol.11 (3), p.1126-1134
issn 2224-5820
2224-5839
language eng
recordid cdi_crossref_primary_10_21037_apm_21_3731
source EZB-FREE-00999 freely available EZB journals
title Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T10%3A14%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Durable%20clinical%20benefit%20from%20afatinib%20in%20a%20lung%20adenocarcinoma%20patient%20with%20acquired%20EGFR%20L718V%20mutation-mediated%20resistance%20towards%20osimertinib:%20a%20case%20report%20and%20literature%20review&rft.jtitle=Annals%20of%20palliative%20medicine&rft.au=Song,%20Zizheng&rft.date=2022-03-01&rft.volume=11&rft.issue=3&rft.spage=1126&rft.epage=1134&rft.pages=1126-1134&rft.issn=2224-5820&rft.eissn=2224-5839&rft_id=info:doi/10.21037/apm-21-3731&rft_dat=%3Ccrossref%3E10_21037_apm_21_3731%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true